[go: up one dir, main page]

WO2002058635A3 - Immunogenes a la nicotine, anticorps et leurs applications - Google Patents

Immunogenes a la nicotine, anticorps et leurs applications Download PDF

Info

Publication number
WO2002058635A3
WO2002058635A3 PCT/US2002/002146 US0202146W WO02058635A3 WO 2002058635 A3 WO2002058635 A3 WO 2002058635A3 US 0202146 W US0202146 W US 0202146W WO 02058635 A3 WO02058635 A3 WO 02058635A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
nicotine
immunogens
nicotine immunogens
immunoreact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/002146
Other languages
English (en)
Other versions
WO2002058635A2 (fr
Inventor
Kim D Janda
Peter Wirsching
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to AU2002251821A priority Critical patent/AU2002251821A1/en
Publication of WO2002058635A2 publication Critical patent/WO2002058635A2/fr
Publication of WO2002058635A3 publication Critical patent/WO2002058635A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des immunogènes utiles dans la production d'anticorps anti-nicotine. Lesdits anticorps sont immunoréactifs vis-à-vis des immunogènes et de la nicotine. Font également l'objet de cette invention les immunogènes et les anticorps utilisés dans le traitement du tabagisme.
PCT/US2002/002146 2001-01-26 2002-01-25 Immunogenes a la nicotine, anticorps et leurs applications Ceased WO2002058635A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002251821A AU2002251821A1 (en) 2001-01-26 2002-01-25 Nicotine immunogens and antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26457501P 2001-01-26 2001-01-26
US60/264,575 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002058635A2 WO2002058635A2 (fr) 2002-08-01
WO2002058635A3 true WO2002058635A3 (fr) 2003-03-20

Family

ID=23006669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002146 Ceased WO2002058635A2 (fr) 2001-01-26 2002-01-25 Immunogenes a la nicotine, anticorps et leurs applications

Country Status (2)

Country Link
AU (1) AU2002251821A1 (fr)
WO (1) WO2002058635A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068335A1 (fr) * 2007-11-29 2009-06-04 Cytos Biotechnology Ag Anticorps monoclonaux humains spécifiques à la nicotine
EP2065398A1 (fr) 2007-11-29 2009-06-03 Cytos Biotechnology AG Anticorps spécifiques à la nicotine monoclonale humaine
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
WO2013130393A1 (fr) * 2012-02-28 2013-09-06 Cornell University Expression persistante dirigée contre aav d'un gène d'anticorps anti-nicotine pour l'abandon du tabac
WO2013154744A1 (fr) * 2012-04-13 2013-10-17 Cornell University Mise au point d'un vaccin conjugué hautement efficace de deuxième génération à base de nicotine destiné à traiter la dépendance à la nicotine
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
EP3668598B1 (fr) 2017-08-15 2025-07-30 BliNK Biomedical SAS Nouveaux anticorps de liaison à la nicotine
WO2019236665A1 (fr) 2018-06-06 2019-12-12 Antidote Therapeutics, Inc. Composition permettant d'améliorer la circulation et de traiter une maladie cardiovasculaire
CN112174763B (zh) * 2020-11-27 2021-04-27 北京邦克凯姆医药科技有限公司 一种吡啶衍生物的消旋方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023076A1 (fr) * 1992-05-20 1993-11-25 The Johns-Hopkins University Therapie utilisant des recepteurs de substitution
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1999061054A1 (fr) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Immunogene a la nicotine
WO2000032239A1 (fr) * 1998-12-01 2000-06-08 Nabi Tonjugues haptene-porteur pour traiter et prevenir l"accoutumance a la nicotine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023076A1 (fr) * 1992-05-20 1993-11-25 The Johns-Hopkins University Therapie utilisant des recepteurs de substitution
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1999061054A1 (fr) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Immunogene a la nicotine
WO2000032239A1 (fr) * 1998-12-01 2000-06-08 Nabi Tonjugues haptene-porteur pour traiter et prevenir l"accoutumance a la nicotine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTRO ET AL.: "Characterization of antibodies to nicotine", BIOCHEMICAL ARCHIVES, vol. 1, 1985, pages 173 - 183, XP002958716 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
US7452541B2 (en) 2002-07-18 2008-11-18 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
US8187607B2 (en) 2002-07-18 2012-05-29 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof

Also Published As

Publication number Publication date
AU2002251821A1 (en) 2002-08-06
WO2002058635A2 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2003045840A3 (fr) Materiaux mesoporeux et procedes de fabrication
MX255058B (es) Derivados de pirazol y proceso para la produccion de los mismos.
AU2002348135A1 (en) Methods for the treatment of addiction
EP1484292A4 (fr) Composition de verre pour preparer des fibres inorganiques, procede de production de ces dernieres et produit ainsi forme a partir de ces dernieres
ZA200204312B (en) Laminate and process for its manufacture.
IL156334A0 (en) Methods for the production of multimeric proteins, and related compositions
AU2002363168A1 (en) Heat-resistant filter layer, filter body and method for the production thereof
MXPA03003302A (es) Proceso y compuestos intermedios para la produccion de anti-estrogenos 7-sustituidos.
AU2002301311A1 (en) Polyacetal resin composition and process for producing the same
WO2002058635A3 (fr) Immunogenes a la nicotine, anticorps et leurs applications
AU2001289695A1 (en) Impregnate, method for the production and use thereof
MXPA03004614A (es) Material estabilizado de crepado posterior y metodo para producir el mismo.
AU2001289955A1 (en) Base material for preparing vitreous or vitrocrystalline parts. method for preparing the base material and method for manufacturing the parts
AU2001295579A1 (en) Pants and method for the production thereof
WO2001049651A3 (fr) Derives d'aminomethyle-phenyle-cyclohexane
AU2001242750A1 (en) Novel protein, process for producing the same and use thereof
AU2002348998A1 (en) N-methyl-homocystines, use thereof and method for the production thereof
IL157793A0 (en) Caloporoside derivatives, methods for the production thereof and their use
IL152795A0 (en) Method for the production of 2-coumarone and substituted 2-coumarones
MXPA03004632A (es) Klainetina y sus derivados, metodo para su produccion y su uso.
ZA200102692B (en) Treated manganese ore, process for producing the same, and use thereof.
WO2004037278A3 (fr) Molecules de delocalisation et leur utilisation
AU2002241418A1 (en) Novel photorefractive materials, intermediate products for producing said materials and method for the production thereof
MXPA03006932A (es) Derivado de indolina y procedimiento para la produccion del mismo.
AU2002215013A1 (en) Polyurethane, method for the production thereof and binding agent produced therefrom

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP